Valuation: US Rare Earth Minerals Inc

Market Cap 2.88M 2.53M 2.33M 2.15M 4.08M 276M 4.16M 28.02M 10.89M 135M 10.81M 10.57M 468M P/E 2024
-5.27x
P/E 2025 -3.28x
Enterprise Value 3.62M 3.17M 2.93M 2.71M 5.13M 347M 5.24M 35.24M 13.69M 170M 13.59M 13.29M 589M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
99.38%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 73 01/09/2018
Director of Finance/CFO 65 01/09/2018
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 71 02/11/2018
Director/Board Member 73 02/11/2018
Chairman 73 01/09/2018
Change 5-day change 1-year change 3-year change Capi.($)
-1.53%+0.78%+72.33%+127.47% 57.72B
-2.45%-7.32%+65.23%+83.15% 52.65B
+3.00%+8.95%+21.26%+471.47% 24.46B
-1.38%-1.14%-16.85%-13.57% 23.84B
-3.05%+3.06%+42.36%-5.66% 19.28B
-0.24%+5.11%+38.76%-25.95% 17.8B
+2.34%+14.18%+220.96%+380.99% 17.29B
-6.73%+9.90%+36.04% - 15.28B
-2.03%+3.30%+28.11%+192.29% 14.35B
Average -1.33%+5.20%+56.47%+151.27% 26.96B
Weighted average by Cap. -1.36%+2.71%+57.73%+139.48%

Financials

2024 2025
Net sales - -
Net income -2.37M -2.08M -1.92M -1.77M -3.36M -227M -3.42M -23.04M -8.95M -111M -8.89M -8.69M -385M -2.12M -1.86M -1.72M -1.59M -3.01M -203M -3.07M -20.67M -8.03M -99.48M -7.97M -7.8M -345M
Net Debt 1.09M 955K 882K 815K 1.54M 104M 1.58M 10.6M 4.12M 51.02M 4.09M 4M 177M 741K 650K 600K 554K 1.05M 70.93M 1.07M 7.21M 2.8M 34.71M 2.78M 2.72M 120M
Logo US Rare Earth Minerals Inc
Bioxytran, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans. The Company's lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with intended applications, which includes the treatment of hypoxic conditions in the brain resulting from stroke. The Company, through its subsidiary, Pharmalectin Inc., is focused on the development, manufacturing, and commercialization of therapeutic drugs designed to address viral diseases in humans. Pharmalectin Inc. has developed a method designed to reduce the viral load and modulate the immune system using a galectin inhibitor. Its lead drug candidate, named ProLectin-Rx, is a complex polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin.
Employees
-